Nath Bio-Genes (India) Limited (NATHBIOGEN) - Net Assets
Based on the latest financial reports, Nath Bio-Genes (India) Limited (NATHBIOGEN) has net assets worth Rs6.80 Billion INR (≈ $73.59 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs10.97 Billion ≈ $118.68 Million USD) and total liabilities (Rs4.17 Billion ≈ $45.09 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Nath Bio-Genes (India) Limited to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs6.80 Billion |
| % of Total Assets | 62.01% |
| Annual Growth Rate | 21.27% |
| 5-Year Change | 25.55% |
| 10-Year Change | 394.57% |
| Growth Volatility | 60.12 |
Nath Bio-Genes (India) Limited - Net Assets Trend (2012–2026)
This chart illustrates how Nath Bio-Genes (India) Limited's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Nath Bio-Genes (India) Limited to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Nath Bio-Genes (India) Limited (2012–2026)
The table below shows the annual net assets of Nath Bio-Genes (India) Limited from 2012 to 2026. For live valuation and market cap data, see NATHBIOGEN market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs6.80 Billion ≈ $73.59 Million |
+5.60% |
| 2025-03-31 | Rs6.44 Billion ≈ $69.69 Million |
+5.65% |
| 2024-03-31 | Rs6.10 Billion ≈ $65.96 Million |
+6.41% |
| 2023-03-31 | Rs5.73 Billion ≈ $61.99 Million |
+5.76% |
| 2022-03-31 | Rs5.42 Billion ≈ $58.61 Million |
-11.63% |
| 2021-03-31 | Rs6.13 Billion ≈ $66.32 Million |
+9.98% |
| 2020-03-31 | Rs5.58 Billion ≈ $60.30 Million |
+9.86% |
| 2019-03-31 | Rs5.08 Billion ≈ $54.89 Million |
+8.17% |
| 2018-03-31 | Rs4.69 Billion ≈ $50.75 Million |
+241.04% |
| 2017-03-31 | Rs1.38 Billion ≈ $14.88 Million |
+13.42% |
| 2016-03-31 | Rs1.21 Billion ≈ $13.12 Million |
+13.22% |
| 2015-03-31 | Rs1.07 Billion ≈ $11.59 Million |
+31.01% |
| 2014-03-31 | Rs817.78 Million ≈ $8.84 Million |
+42.29% |
| 2013-03-31 | Rs574.74 Million ≈ $6.22 Million |
+25.69% |
| 2012-03-31 | Rs457.28 Million ≈ $4.95 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nath Bio-Genes (India) Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs190.04 Million | 2.79% |
| Other Components | Rs6.61 Billion | 97.21% |
| Total Equity | Rs6.80 Billion | 100.00% |
Nath Bio-Genes (India) Limited Competitors by Market Cap
The table below lists competitors of Nath Bio-Genes (India) Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Corentec Co Ltd
KQ:104540
|
$35.35 Million |
|
SJM Co Ltd
KO:123700
|
$35.37 Million |
|
Hammer Metals Ltd
AU:HMX
|
$35.37 Million |
|
Q linea AB
ST:QLINEA
|
$35.38 Million |
|
RS GROUP PLC
LSE:RS1
|
$35.34 Million |
|
Wiseway Group Ltd
AU:WWG
|
$35.33 Million |
|
Rossmax International Ltd
TWO:4121
|
$35.33 Million |
|
WINSON Machinery Co Ltd
TWO:4538
|
$35.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nath Bio-Genes (India) Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 6,443,871,000 to 6,804,588,000, a change of 360,717,000 (5.6%).
- Net income of 416,303,000 contributed positively to equity growth.
- Dividend payments of 38,008,000 reduced retained earnings.
- Other comprehensive income decreased equity by 156,097,000.
- Other factors increased equity by 138,519,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs416.30 Million | +6.12% |
| Dividends Paid | Rs38.01 Million | -0.56% |
| Other Comprehensive Income | Rs-156.10 Million | -2.29% |
| Other Changes | Rs138.52 Million | +2.04% |
| Total Change | Rs- | 5.60% |
Book Value vs Market Value Analysis
This analysis compares Nath Bio-Genes (India) Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.50x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 6.02x to 0.50x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-03-31 | Rs28.57 | Rs172.01 | x |
| 2013-03-31 | Rs35.91 | Rs172.01 | x |
| 2014-03-31 | Rs51.10 | Rs172.01 | x |
| 2015-03-31 | Rs66.94 | Rs172.01 | x |
| 2016-03-31 | Rs75.80 | Rs172.01 | x |
| 2017-03-31 | Rs85.97 | Rs172.01 | x |
| 2018-03-31 | Rs276.18 | Rs172.01 | x |
| 2019-03-31 | Rs267.09 | Rs172.01 | x |
| 2020-03-31 | Rs293.42 | Rs172.01 | x |
| 2021-03-31 | Rs322.71 | Rs172.01 | x |
| 2022-03-31 | Rs285.19 | Rs172.01 | x |
| 2023-03-31 | Rs301.61 | Rs172.01 | x |
| 2024-03-31 | Rs320.94 | Rs172.01 | x |
| 2025-03-31 | Rs336.21 | Rs172.01 | x |
| 2026-03-31 | Rs342.92 | Rs172.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nath Bio-Genes (India) Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.12%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.35%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 1.61x
- Recent ROE (6.12%) is below the historical average (10.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 20.12% | 7.42% | 1.03x | 2.62x | Rs46.28 Million |
| 2013 | 20.44% | 8.53% | 0.87x | 2.75x | Rs59.98 Million |
| 2014 | 29.72% | 12.83% | 1.00x | 2.32x | Rs161.26 Million |
| 2015 | 23.71% | 13.70% | 0.82x | 2.11x | Rs146.84 Million |
| 2016 | 11.68% | 8.74% | 0.61x | 2.20x | Rs20.37 Million |
| 2017 | 11.83% | 9.59% | 0.59x | 2.10x | Rs25.24 Million |
| 2018 | 6.27% | 15.35% | 0.34x | 1.22x | Rs-175.05 Million |
| 2019 | 7.57% | 16.67% | 0.36x | 1.27x | Rs-123.25 Million |
| 2020 | 9.05% | 18.04% | 0.38x | 1.31x | Rs-52.78 Million |
| 2021 | 9.08% | 18.11% | 0.39x | 1.29x | Rs-56.66 Million |
| 2022 | -12.42% | -24.19% | 0.38x | 1.37x | Rs-1.22 Billion |
| 2023 | 6.11% | 11.62% | 0.38x | 1.38x | Rs-223.06 Million |
| 2024 | 6.50% | 16.01% | 0.28x | 1.44x | Rs-213.73 Million |
| 2025 | 5.99% | 10.58% | 0.36x | 1.59x | Rs-258.39 Million |
| 2026 | 6.12% | 9.35% | 0.41x | 1.61x | Rs-264.16 Million |
Industry Comparison
This section compares Nath Bio-Genes (India) Limited's net assets metrics with peer companies in the Agricultural Inputs industry.
Industry Context
- Industry: Agricultural Inputs
- Average net assets among peers: $8,394,350,800
- Average return on equity (ROE) among peers: 14.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nath Bio-Genes (India) Limited (NATHBIOGEN) | Rs6.80 Billion | 20.12% | 0.61x | $35.35 Million |
| Agro Phos India Limited (AGROPHOS) | $230.94 Million | 10.43% | 2.11x | $6.87 Million |
| Astec LifeSciences Limited (ASTEC) | $325.25 Million | 31.90% | 2.00x | $191.29 Million |
| Bayer Cropscience Limited (BAYERCROP) | $18.83 Billion | 17.90% | 0.54x | $2.07 Billion |
| Best Agrolife Limited (BESTAGRO) | $7.58 Billion | 9.23% | 1.57x | $60.72 Million |
| Bhagiradha Chemicals & Industries Limited (BHAGCHEM) | $461.53 Million | -6.95% | 2.88x | $363.19 Million |
| Bharat Rasayan Limited (BHARATRAS) | $294.66 Million | 2.97% | 0.30x | $258.37 Million |
| Bohra Industries Limited (BOHRAIND) | $385.55 Million | 11.70% | 2.11x | $1.83 Million |
| Bombay Super Hybrid Seeds Limited (BSHSL) | $394.91 Million | 26.60% | 1.47x | $104.66 Million |
| Chambal Fertilizers & Chemicals Limited (CHAMBLFERT) | $24.18 Billion | 20.63% | 2.92x | $2.09 Billion |
| Coromandel International Limited (COROMANDEL) | $31.26 Billion | 22.12% | 2.11x | $6.59 Billion |
About Nath Bio-Genes (India) Limited
Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities. The company offers fiber and oil seeds, including cotton and mustard; plant nutrient supplements; pearl millets; seeds for field crops, such as bajra, maize, corn, paddy, wheat, and jow… Read more